| Budget Amount *help |
¥42,510,000 (Direct Cost: ¥32,700,000、Indirect Cost: ¥9,810,000)
Fiscal Year 2019: ¥8,320,000 (Direct Cost: ¥6,400,000、Indirect Cost: ¥1,920,000)
Fiscal Year 2018: ¥8,320,000 (Direct Cost: ¥6,400,000、Indirect Cost: ¥1,920,000)
Fiscal Year 2017: ¥8,320,000 (Direct Cost: ¥6,400,000、Indirect Cost: ¥1,920,000)
Fiscal Year 2016: ¥8,320,000 (Direct Cost: ¥6,400,000、Indirect Cost: ¥1,920,000)
Fiscal Year 2015: ¥9,230,000 (Direct Cost: ¥7,100,000、Indirect Cost: ¥2,130,000)
|
|---|
| Outline of Final Research Achievements |
Kinase fusion oncogenes have been reported to be involved in tumorigenesis. Thus, it is speculated that the kinase fusion-oncogene products are the promising therapeutic targets for the kinase fusion-positive cancers, and many pharmaceutical companies have developed kinase inhibitors as therapeutic agents. The developed kinase inhibitors have elicited remarkable anti-tumor effects in the kinase-fusion positive cancers in the early stages of administration, however, tumors gradually develop resistance to the drugs. Integrated genetic, molecular and cellular analysis of the resistant tumor cells found in the relapsed tumors resulted in the identification of novel resistant mutations in ALK-, ROS1-, NTRK1-positive cancers. Drug screening using the resistant mutation-positive cancers also resulted in the identification of the overcoming drugs.
|
